cytochrome P450 family 4 subfamily A member 26, pseudogeneGenealiases: []
Q-omics provides the consensus-scored CYP4A26P profile across patient tissues and cancer cell-line models. CYP4A26P expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, CYP4A26P is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, CYP4A26P RNA expression shows 9,493 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight THYM, LUSC, and LUAD as cancer lineages where CYP4A26P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP4A26P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP4A26P survival associations across molecular data types. CYP4A26P RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP4A26P RNA expression–survival associations across cancer types. High CYP4A26P expression shows unfavorable associations in THYM, STAD, SKCM, COAD and THCA, but favorable associations in LUAD. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for CYP4A26P RNA expression.
This table summarizes CYP4A26P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP4A26P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP4A26P shows lower tumor expression in LUSC and LUAD. The LUSC box plot shows higher CYP4A26P RNA expression in normal versus tumor tissue (log2 FC = −0.397, t-test p < 0.001).
This table shows molecular features associated with CYP4A26P in patient tissues and cancer cell lines. In patient samples, CYP4A26P shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
